Literature DB >> 12780792

Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias.

Stefano Luminari1, Maria Goldaniga, Fulvia Ceccherelli, Andrea Guffanti, Emilio Bombardieri, Raffaella Marcheselli, Lilla Cro, Mariangela Colombi, Massimo Federico, Luca Baldini.   

Abstract

High serum Mucin-1 (sMUC-1) levels have been shown in patients with adenocarcinoma and multiple myeloma (MM). We evaluated sMUC-1 levels in 76 patients with MM, 6 with plasma cells leukaemia (PCL) and 89 with monoclonal gammopathy of undetermined significance, to establish prevalence data and verify its possible prognostic role. Of the 171 patients, 27 [16%; 95% confidence interval (CI): 10-21%] had high sMUC-1 levels compared with healthy subjects (1.5%; 95% CI: 0-4%). Elevated sMUC-1 levels in MM and PCL patients correlated with anaemia and elevated serum lactate dehydrogenase levels; these patients showed a shorter survival than those with normal sMUC-1 levels (median overall survival: 25 vs. 49 months, P = 0.003).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12780792     DOI: 10.1046/j.1365-2141.2003.04353.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  1 in total

1.  Autoantibodies against the signal peptide domain of MUC1 in patients with multiple myeloma: Implications for disease diagnosis and prognosis.

Authors:  Riva Kovjazin; Anna Dubnik; Galit Horn; Nechama I Smorodinsky; Izhar Hardan; Michael Yechiel Shapira; Lior Carmon
Journal:  Exp Ther Med       Date:  2012-04-03       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.